Primarily, conjugation of TRAIL and other DR5-specific molecules with nanoscaled carriers pursues a goal to enhance ligand stability and pharmacokinetic profile, as well as to increase nanocarrier accumulation in the tumor due to enhanced permeability and retention (EPR) effect. Here, TNFRSF10B is linked to neoplasm.